# BPC-157 Dr. — Independent research summary on Body Protection Compound 157 > Plain-language summary of the BPC-157 (Body Protection Compound 157) research literature: mechanism, animal studies, pharmacokinetics, three published human reports, and regulatory status. A fifteen-amino-acid peptide. Thirty-plus years of rodent studies. Three small human reports. One regulatory file marked Category 2. Here is what the literature actually says. ## § 00 The short version BPC-157 is a synthetic fifteen-amino-acid peptide derived from a protein found in human gastric juice. It is studied for tissue repair across tendons, muscle, bone, gut and the nervous system — all in rodent models. Thirty-plus years of animal work describes consistent repair effects at multiple levels of biology. The human data are a different story: three small, uncontrolled reports from a single investigator group, none of them a randomized controlled trial. The FDA placed BPC-157 on its Category 2 list in 2023, excluding it from pharmacy compounding. WADA prohibits it in sport. No regulatory body has approved it for any human indication. That is the complete official evidence picture. For what people report using it — benefits and adverse effects — see [the effects page](/effects). ## § 01 The compound BPC-157 is a synthetic peptide of fifteen amino acids — the sequence GEPPPGKPADDAGLV — drawn from a larger cytoprotective protein found in human gastric juice [11]. It is also catalogued as Pentadecapeptide BPC 157, PL 14736, PL-10, and PLD-116. Its molecular weight is 1419.55 Da. Its CAS number is 137525-51-0. Its defining structural feature is three consecutive prolines at positions 3, 4, and 5, which appears to confer resistance to gastric proteolysis and allows researchers to administer it in drinking water in many rodent studies [11]. This site is a reading of the literature. It is not a clinic. It does not prescribe, dispense, or recommend. ## § 02 What the studies describe Across more than three decades of preclinical work, BPC-157 has been studied as a multi-pathway cytoprotectant. Reports describe modulation of the nitric oxide system through endothelial nitric oxide synthase (eNOS), promotion of angiogenesis through the VEGFR2-PI3K-Akt-eNOS pathway, and engagement of ERK1/2 MAPK and FAK-paxillin signaling relevant to fibroblast migration and collagen organization [4][20]. In transected rat Achilles tendons, BPC-157 at 10 μg/kg or 10 ng/kg intraperitoneal increased load-to-failure, improved collagen and reticulin organization, and restored macroscopic tendon integrity [1]. In rabbit segmental bone defects, 10 μg/kg produced bony union comparable to autologous cortical bone grafting [5]. In a 2025 rat model of surgically detached quadriceps muscle, per-oral BPC-157 in drinking water closed the muscle-bone gap by day 21-28 and restored walking pattern [14]. In gastrointestinal models, the peptide is reported to reduce anastomotic leakage and increase burst pressures across esophagogastric, colocolonic, jejunoileal, and ileoileal segments in rats [13], and to close colocutaneous, duodenocolic, and tracheocutaneous fistulas [7][19][23]. ## § 03 Pharmacokinetics He et al. (2022) profiled BPC-157 in Sprague-Dawley rats and beagle dogs after intramuscular dosing. Intramuscular bioavailability was 14-19% in rats and 45-51% in dogs. Tmax was approximately 3 minutes in rats and 6-9 minutes in dogs. Plasma half-life was under 30 minutes in both species. Metabolism produced six small peptide fragments; elimination was urinary and biliary [11]. The peptide's stability in gastric juice — the original premise of its discoverers — has been confirmed across many rodent protocols, where drinking-water administration produces measurable biological effects. Oral bioavailability has not been formally quantified in healthy humans. ## § 04 Where the evidence stops A 2025 systematic review in *HSS Journal* indexed thirty-six BPC-157 articles published between 1993 and 2024. Thirty-five were preclinical. One was clinical [16]. That ratio is the single most important fact on this page. The entire published human file is three small uncontrolled reports from a single investigator group between 2021 and 2025: intra-articular injection in 16 knees, intravesicular injection in 12 bladders, and a single-arm intravenous infusion in healthy volunteers [17]. None is a controlled trial. None has been replicated by an independent group. In September 2023 the U.S. Food and Drug Administration placed BPC-157 on its Category 2 list of bulk drug substances that may present significant safety risks, excluding it from 503A pharmacy compounding. The World Anti-Doping Agency added it to the Prohibited List under section S0 (Non-Approved Substances), effective 1 January 2022 [16][18]. ## § 05 Mechanism in three sentences The peptide is described as multi-pathway. Across in vivo rodent work, it acts through the VEGFR2-PI3K-Akt-eNOS axis to promote angiogenesis [4], modulates all three nitric oxide synthase isoforms in a substrate-independent fashion [7][20], upregulates the growth hormone receptor in tendon fibroblasts via JAK2 [2], shifts macrophage polarization toward the M2 anti-inflammatory phenotype, and engages the FAK-paxillin pathway in fibroblast migration and collagen organization. None of these mechanisms have been validated in controlled human trials. In vitro angiogenic assays on isolated cells are negative — the in vivo effect appears to require the wound microenvironment. ## § 06 How to read this site Six pages of substance. */research* catalogues the preclinical evidence by tissue and mechanism. */dosage* reports dose ranges in the species and route in which they were studied — no human translation, no protocols, no recommendations. */effects* summarizes the reported effects and the safety cautions the literature raises. */faq* answers the questions a careful reader brings to the literature. */references* lists every cited study with DOI and link. */about* explains what this publication is and is not. */contact* is for editorial correspondence only. This is an editorial digest of the published research — nothing is offered for sale here, no vendor is referred to, and no human dose is suggested. The publication runs no analytics, no trackers, no third-party scripts. Every page has a markdown alternate at `/path.md` for AI agents and crawlers; a curated reading list at `/llms.txt`; and a single-file concatenation at `/llms-full.txt`. All three are linked from the footer. --- A modernist reading of the published literature — not a clinical opinion.